-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Treatment of Hemophagocytic Lymphohistiocytosis in Adults

Program: Education Program
Session: Hemophagocytic Lymphohistiocytosis in Adults
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Hall E2, Level 2 (Orange County Convention Center)
Monday, December 7, 2015, 7:00 AM-8:30 AM
Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

Paul La Rosée, Prof. Dr. med.

Klinik für Innere Medizin II, Abt. Hämatologie u. internist. Onkologie, Jena University Hospital, Jena, Germany

Disclosures: La Rosée: Pfizer: Consultancy , Honoraria ; Novartis: Consultancy , Honoraria , Research Funding ; Roche: Consultancy , Honoraria , Speakers Bureau ; CTI Lifesciences: Honoraria ; Janssen-Cilag: Honoraria ; Gilead: Consultancy , Honoraria , Speakers Bureau ; Bristol-Myers-Squibb: Honoraria , Research Funding ; Mundipharma: Other: Travel support ; Takaeda: Consultancy , Honoraria , Other: travel support ; Celgene: Honoraria . Off Label Use: Rituximab, EBV-triggered HLH; Tocilizumab, HLH triggered by Blinatumomab or CAR T-cells..

See more of: Hemophagocytic Lymphohistiocytosis in Adults
See more of: Education Program
<< Previous Presentation | Next Presentation